AbbVie’s projected 2025 earnings just got trimmed by Cantor Fitzgerald, slicing estimates from $12.31 per share to $11.84.

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right typ ...

Silver's future contracts with September expiry hit a lifetime high of over Rs Rs 1.11 lakh per kg on the MCX.

Glenmark Share Price: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent in early trade on Friday, scaling a new ...

Shares of Glenmark gained 10% to Rs 2,094 on July 11, making it a top gainer on the Nifty Midcap 150 index. Mankind Pharma, NMDC, Gland, and Alkem Lab were also among the top gainers. Moneycontrol ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

AbbVie (ABBV) closed the most recent trading day at $195.00, moving +2.3% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered ...

This was the stock's third consecutive day of gains.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...